The Column Group β 2024 Investments
6 investments dated 2024 Β· listed companies and verified rows first Β· show all
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)
Board seatJeff GoaterΒ· per SEC Form D
Co-investorsAtlas VentureForesite CapitalARCH Venture PartnersDecheng Capital
BiotechCambridge, US
Peter Fuhrken(Director)Howard Federoff(Executive Officer, Director)Nick Manusos(Executive Officer, Director)Martin Ostrowski(Executive Officer)Jonathan Yeh(Director)
Board seatJeff GoaterΒ· per SEC Form D Β· $81.8M raise Β· filed Mar 2024
Co-investorsCure Ventures
HealthtechSan Francisco, US
Alexander Marson(Director)
BoardAadit Shah(Executive Officer)
Board seatTim KutzkeyΒ· per SEC Form D Β· $15M raise Β· filed Apr 2024
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)JJDCJohnson & Johnson Innovation β JJDC+1 more
BiotechNew York, US
Jeff Goater(Executive Officer, Director)
BoardTim Kutzkey(Executive Officer, Director, Promoter)
Co-investorsDCVC (Data Collective)DCVC BioLux Capital
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.